Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics Inc. reported a significant 76% year-over-year revenue increase in Q3 FY25, driven primarily by contributions from the SCN integration, which has demonstrated the potential to accelerate adoption and revenue growth with minimal additional investment. Service revenues more than doubled, reaching $4.6 million, emphasizing the company's successful expansion into sleep testing and treatment-center revenue streams. Additionally, the strong clinical outcomes reported—where 77% of patients with moderate or severe obstructive sleep apnea improved significantly—coupled with projected market growth in the Asia Pacific region, positions Vivos favorably for continued revenue expansion and market penetration.

Vivos Therapeutics Inc has experienced a year-over-year revenue decline of 9% in the first half of 2025, as the company transitions to a new sleep center operations model, which has resulted in revenues falling short of estimates. The gross margins have also decreased to 55% due to discounting and a shift in their product and service mix, reflecting challenges in maintaining profitability amid this transition. Furthermore, the company faces multiple risks, including the potential for lower-than-expected sales growth and ongoing concerns about capital acquisition and market penetration, alongside a history of operating losses and negative cash flow, which contribute to a pessimistic outlook for its financial stability.